UPDATE: Cowen Starts Angion Biomedica (ANGN) at Outperform

Cowen analyst Marc Frahm initiates coverage on Angion Biomedica (NASDAQ: ANGN) with an Outperform rating.

The analyst commented, "Angion develops small molecules to treat organ injury and fibrotic disease. ANG-3777 is a hepatocyte growth factor (HGF) mimetic with a fully enrolled Ph3 for delayed graft function (DGF). Data is expected by YE:21. A Ph2 in cardiac surgery-associated AKI will report data in H2:21. With partner Vifor's help, we believe these conditions can support ~$1.5B in sales and drive shares to outperform."

For an analyst ratings summary and ratings history on Angion Biomedica click here. For more ratings news on Angion Biomedica click here.

Shares of Angion Biomedica closed at $19.92 yesterday.

You May Also Be Interested In

• Siemens AG (SIE:GR) (SIEGY) PT Raised to EUR170 at Jefferies
• ESR Cayman Ltd (1821:HK) (ESRCF) PT Raised to HK$29.20 at Morgan Stanley
• Shinhan Financial Group (055550:KS) (SHG) PT Raised to KRW48,000 at Morgan Stanley